Coave's Gene Therapy Aims to End Frequent Eye Injections for AMD

PARIS, France – April 22, 2026 – A French biotechnology company is set to unveil preclinical data on a novel gene therapy that could one day free millions of patients with wet age-related macular degeneration (wAMD) from the relentless cycle of frequent, uncomfortable eye injections. Coave Therapeutics announced it will present its lead program, CoTx-101, at two major ophthalmology conferences in May, showcasing a technology designed to be a one-and-done treatment for the leading cause of severe vision loss and blindness in people over age 65.

The upcoming presentations at the Eyecelerator @ ARVO innovation meeting and the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting in Denver, Colorado, are poised to draw significant attention from clinicians, researchers, and investors. The company's approach tackles one of the most significant challenges in modern medicine: delivering gene therapy to the right place, at the right time, with lasting effect.

A New Paradigm for Treating Retinal Disease

For years, the standard of care for wAMD has been anti-VEGF therapy, which involves injecting drugs directly into the vitreous of the eye. While these treatments are effective at slowing disease progression and preserving vision, they place an immense burden on patients, their families, and the healthcare system. The regimen often requires visits to a retina specialist every one to three months for injections, a demanding schedule that continues indefinitely.

This cycle of repeat injections carries not only a risk of complications like infection and retinal detachment but also a significant psychological and logistical toll. The prospect of a durable, long-term solution has therefore become a holy grail in ophthalmic research.

Coave Therapeutics aims to provide that solution with CoTx-101. The company describes it as a next-generation gene therapy that combines a best-in-class, in-office delivery procedure with a first-in-class vector. The goal is to have a patient receive a single administration that enables their own retinal cells to produce therapeutic proteins continuously, effectively transforming the eye into its own bioreactor. This would eliminate the need for repeat injections while providing stable, long-term vision gains.

The Science of Precision Delivery

At the heart of Coave's innovation is its proprietary technology platform, designed to overcome the critical challenge of gene therapy: delivery. The company's system is built on several sophisticated components.

First is the delivery route. Instead of a standard injection into the center of the eye (intravitreal), Coave utilizes the suprachoroidal space (SCS). This is a potential space between the sclera (the white of the eye) and the choroid (the vascular layer beneath the retina). Administering therapy into this space allows for broad and targeted distribution across the retina and choroid—the very tissues affected by wAMD—using a procedure that is less invasive than a surgical subretinal injection.

Second, and most distinctively, is the vector itself. Coave has engineered a ligand-conjugated adeno-associated virus (AAV) vector, which it calls coAAV-SCS. AAVs are harmless, modified viruses commonly used as delivery vehicles in gene therapy. Coave enhances this vehicle using its ALIGATER™ platform, which attaches specific molecules, or ligands, to the AAV's surface. These ligands act like a molecular key, designed to bind to specific receptors on target cells in the retina. This 'precision guidance' system is intended to ensure the vector delivers its genetic payload exactly where it's needed, enhancing efficacy and safety. The company claims this approach achieves "unprecedent posterior segment targeting" in non-human primate studies.

Finally, the payload of CoTx-101 is designed for a powerful effect. It is a dual-pathway therapy, meaning the genetic instructions it carries will prompt the eye to produce two different clinically validated biologics that target the angiogenesis pathway, the process of abnormal blood vessel growth that defines wAMD.

Stepping onto the Global Stage at ARVO 2026

The choice of venue for unveiling this data is significant. The ARVO Annual Meeting is the world's premier gathering for eye and vision researchers, while the preceding Eyecelerator meeting connects innovators with the capital and strategic partners needed to bring new treatments to market. Presenting at both signals Coave's confidence in its science and its strategy to move toward clinical trials.

Coave's CEO, Rodolphe Clerval, will present a company overview at Eyecelerator on May 1. This will be followed by two key poster presentations at ARVO. On May 5, Chief Scientific Officer Lolita Petit will detail the novel suprachoroidal vector and its performance in non-human primate studies. Two days later, Brahim Belbellaa, Senior Director of Preclinical Ophthalmology, will present on the CoTx-101 program itself, outlining its potential for treating retinal vascular diseases.

Fittingly, the theme for ARVO 2026 is "Achieving precision ophthalmology through innovative vision research." Coave's highly targeted, ligand-conjugated vector technology aligns perfectly with this theme, representing a clear example of the field's push toward more personalized and effective treatments.

Navigating a Competitive Landscape

Coave Therapeutics is not alone in the race to develop a long-acting treatment for wAMD. The field is bustling with innovation, as several companies are pursuing gene therapies and other novel approaches.

Competitors like REGENXBIO are also exploring suprachoroidal delivery for their gene therapy candidate, RGX-314, while Adverum Biotechnologies is focused on an intravitreally delivered gene therapy. Beyond gene therapy, the market has already seen the introduction of longer-acting drugs like Genentech's Vabysmo, a bispecific antibody, and the Port Delivery System (Susvimo), which reduce but do not eliminate the need for clinic visits.

Against this backdrop, Coave's combination of a ligand-conjugated vector for enhanced precision, a dual-biologic payload for robust efficacy, and a convenient suprachoroidal delivery route represents a unique and potentially best-in-class strategy. Success in the upcoming preclinical presentations will be a critical step in validating this approach.

The data to be shared in Denver will be carefully scrutinized, as it represents the first major public look at the foundational technology behind CoTx-101. While the path from preclinical studies to an approved therapy is long and challenging, the promise of a one-time treatment for one of the world's most debilitating eye diseases marks a hopeful and potentially transformative moment in ophthalmology. If successful, Coave's 'plug-and-play' platform could also be applied to other vectors and payloads, opening the door to treating a host of other prevalent diseases previously considered beyond the reach of gene therapy.